New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
New post-hoc data from Eli Lilly's Phase 3 LUCENT-2 and VIVID-1 trials show Omvoh-treated patients achieved composite multidimensional outcomes at one year, including 27.7% comprehensive disease control in ulcerative colitis versus 14% on placebo. In Crohn's disease, 20.4% of Omvoh patients achieved corticosteroid-free deep remission versus 2% on placebo, with benefits persisting in prior biologic-failure populations.
Key figures
- Drug Name
- Omvoh (mirikizumab-mrkz)
- Phase Of Trial
- Phase 3
- Countries approved
- 47
- Uc biologic failure control
- 23.4% vs 9.4% placebo
- Cd steroid free deep remission
- 20.4% vs 2% placebo (VIVID-1)
- Uc comprehensive disease control
- 27.7% vs 14% placebo (LUCENT-2)
- Cd biologic failure deep remission
- 15.7% vs 0% placebo
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.